| Jan 8, 2026 | Parabilis Medicines | $305.0M Series F | Jake Simson | Catalio Capital Management, Foresite Capital, ARCH Venture Partners, Cormorant Asset Management, Farallon Capital Management, Frazier Life Sciences, Freepoint Capital Group, General Catalyst, HBM Healthcare Investments, Invus, Marshall Wace, Milky Way Investments, Nextech Invest, Sixty Degree Capital, Soleus Capital, T. Rowe Price Associates |
| Oct 1, 2025 | GammaTime | $14.0M Seed | Pitango Venture Capital, VGames | Alumni Ventures, Seven Seven Six, Slow Ventures, Kris Jenner, Alexis Ohanian, Kim Kardashian, Kris Jenner, Traverse Ventures |
| Oct 1, 2025 | Hemab | $160.0M Series C | Soffinova Partners | Access Biotechnology, Amzak Health Investors, HealthCap, Avoro Capital Advisors, Deep Track Capital, Invus, Maj Invest, Novo Holdings, RA Capital Management |
| Sep 3, 2025 | Treeline Biosciences | $200.0M Series A Extension | — | AI Life Sciences, Aisling Capital, Ajax Health, ARCH Venture Partners, Casdin Capital, Exor, Fidelity Management & Research Company, Google Ventures, KKR, OrbiMed, T. Rowe Price Associates |
| Sep 1, 2025 | Phia | $8.0M Seed | Kleiner Perkins | Mark Cuban, Michael G. Rubin, Desiree Gruber, Hailey Bieber, Kris Jenner, Sara Blakely, Sheryl Sandberg, Kris Jenner, Soma Capital |
| Jul 25, 2024 | Imperative Care | $150.0M Series E | Frank Yu | AMED Ventures, Bain Capital Life Sciences, Catalio Capital Management, D1 Capital Partners, HealthCor Family Office, Innovatus Capital Partners, INTAI Technology, Montreux Equity Partners, Pura Vida Investments |
| May 1, 2024 | Zenas BioPharma | $200.0M Series C | SR One Capital Management, Tim Xiao, NEA, Norwest Venture Partners | Vivo Capital, ArrowMark Partners, Enavate Sciences, Fairmount, Hermes GPE, Longitude Capital, Pivotal bioVenture Partners, Quan Capital, Superstring Capital, Wellington Management |
| Feb 1, 2024 | FogPharma | $150.0M Series E | Thilo Schroeder | Lux Capital, Nextech Invest, The Column Group, venBio, Alex Gorsky, ARCH Venture Partners, Catalio Capital Management, Cormorant Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Foresite Capital, General Catalyst, Google Ventures, Invus, Marshall Wace, Milky Way Investments, RA Capital Management, Samsara BioCapital, Sixty Degree Capital, SymBiosis, T. Rowe Price Associates |
| Jan 2, 2024 | Apollo Therapeutics | $33.5M Series C | Jim Momtazee | M&G Investments |
| Sep 1, 2023 | Avalyn Pharma | $180.0M Series C | SR One, Eventide Asset Management, Gianna Hoffman-Luca | B Capital Group, Northpond Ventures, Heather Preston, Catalio Capital Management, F-Prime Capital, Norwest Venture Partners, Novo Holdings, Pivotal bioVenture Partners, RiverVest Venture Partners, Surveyor Capital, T. Rowe Price Associates, Vida Ventures, Wellington Management |
| Aug 1, 2023 | Genesis Therapeutic | $200.0M Series B | Vijay Pande, PhD | Andreessen Horowitz, Pillar VC, VZVC, BlackRock, Fidelity Management & Research Company, Menlo Ventures, NVentures, Radical Ventures, T. Rowe Price Associates |
| Feb 1, 2023 | Hemab | $140.0M Series B | Access Biotechnology | Amzak Health Investors, Soffinova Partners, Uya Chuluunbaatar, Deep Track Capital, Marten Steen, Invus, Maj Invest, Jørgen Søberg Petersen, RA Capital Management |
| Nov 1, 2022 | Zenas BioPharma | $120.0M Series B | James Boylan | venBio, Vivo Capital, Agent Capital, Fairmount, Patrick Enright, Perceptive Advisors, Pivotal bioVenture Partners, Quant Venture Fund, Superstring Capital, Tellus BioVentures, Wellington Management, Xencor |
| Jul 1, 2022 | Delfi Diagnostics | $230.0M Series B | Justin Kao | Canvas Ventures, DFJ Growth, Jenny Fielding, Scott Hartley, Menlo Ventures, OrbiMed, Westlake Village BioPartners, AV8 Ventures, Brown Advisory, Cowen Healthcare Investments, Eli Lilly and Company, Foresite Capital, Illumina Ventures, Initiate Ventures, Menlo Ventures, Northpond Ventures, Open Field Capital, Point72, Point Field Partners, PTX Capital, Samsara BioCapital, T. Rowe Price Associates, Windham Venture Partners |
| Jun 1, 2022 | Mineralys Therapeutics | $120.0M Series B | Andera Partners, Derek DiRocco | Access Biotechnology, Arix Bioscience, Atlas Venture, Canaan Partners, RA Capital, Versant Ventures, Ysios Capital, Boulder Ventures, Catalys Pacific, HBM Healthcare Investments, HealthCor, RTW Investments, Samsara BioCapital, Sectoral Asset Management, SR One |
| May 10, 2022 | MOMA Therapeutics | $150.0M Series B | Amit Sinha, Amit Sinha | Alexandria Venture Investments, Casdin Capital, Cormorant Asset Management, Creacion Ventures, Invus, LifeSci Venture Partners, MOMA Therapeutics, Nextech Invest, Pavilion Capital, Section 32, Third Rock Ventures |
| Jan 10, 2022 | AvengeBio | $45.0M Series A | Ben Askew, CAM Capital, Perceptive Xontogeny Venture Fund | Josh Richardson, Pappas Capital |
| Jan 1, 2022 | Simcha Therapeutics | $40.0M Series B | SR One | Westlake Village BioPartners, ArrowMark Partners, BVF Partners, Logos Capital, Samsara BioCapital |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena El-Bibany, Vasudev Bailey, Artis Ventures (AV), Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, RA Capital, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, ArrowMark Partners, BrightEdge Ventures, Byers Capital, Catalio Capital Management, Data Collective, Eventide Asset Management, Farallon Capital Management, Fidelity Management & Research Company, Google Ventures, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Ridgeback Capital Investments, Thomas Schinecker, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Oct 26, 2021 | Patina | $57.0M Series A | Andreessen Horowitz, Google Ventures | F-Prime Capital, Viking Global Investors |
| Oct 5, 2021 | Honor | $370.0M Debt / Series E | Perceptive Advisors | Lori Hogan, Paul Hogan, Andreessen Horowitz, Ares Management, FMZ Ventures, Lighthouse Capital Markets, Prosus Ventures, Thrive Capital, TriplePoint Capital, T. Rowe Price Associates |
| Oct 1, 2021 | CinCor Pharma | $140.0M Series B | Jason Pitts | ARCH Venture Partners, Keno Gutierrez, Soffinova Partners, Sofinnova Investments, Third Rock Ventures, Westlake Village BioPartners, David Morris, Heather Preston, Adage Capital Management, BVF Partners, CinCor Pharma, CinRx Pharma, Lilly Asia Ventures, Omega Funds, Perceptive Advisors, RTW Investments, Sixty Degree Capital |
| Sep 2, 2021 | Disc Medicine | $90.0M Series B | Mona Ashiya | 5AM Ventures, Access Biotechnology, Alexandria Venture Investments, Mark Chin, Atlas Venture, John Quisel, Janus Henderson Investors, Nantahala Capital Management, Novo Holdings, Willett Advisors |
| Jul 20, 2021 | Amylyx Pharmaceuticals | $135.0M Series C | Viking Global Investors | Belinda Termeer, 683 Capital Management, Bain Capital Life Sciences, Falcon Edge Capital, Marshall Wace, Morningside Ventures, Perceptive Advisors, Polaris Founders Capital, Tybourne Capital Management, Verition Fund Management, Woodline Partners |
| Jul 15, 2021 | Imperative Care | $260.0M Series D | Daniel Saul Sundheim | Ally Bridge Group, AMED Ventures, Ascension Ventures, Bain Capital Life Sciences, Delos Capital, HealthCor, Innovatus Capital Partners |
